Handelsbanken Fonder AB Buys Shares of 18,400 Twist Bioscience Co. (NASDAQ:TWST)

Handelsbanken Fonder AB bought a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 18,400 shares of the company's stock, valued at approximately $855,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its position in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company's stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock valued at $61,807,000 after acquiring an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans bought a new stake in Twist Bioscience during the 3rd quarter worth $43,992,000. Wellington Management Group LLP increased its holdings in Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock worth $36,042,000 after purchasing an additional 521,272 shares in the last quarter. Finally, Fred Alger Management LLC boosted its stake in shares of Twist Bioscience by 17.1% during the third quarter. Fred Alger Management LLC now owns 767,149 shares of the company's stock valued at $34,660,000 after purchasing an additional 112,272 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Robert W. Baird lifted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Barclays set a $58.00 price objective on Twist Bioscience and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Finally, TD Cowen restated a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $54.40.

Remove Ads

Insider Buying and Selling at Twist Bioscience

In other news, Director Robert Chess sold 2,940 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares in the company, valued at $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 5,200 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $256,620.00. Following the completion of the transaction, the chief executive officer now owns 667,318 shares in the company, valued at $32,932,143.30. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,180 shares of company stock worth $1,821,971. Insiders own 3.01% of the company's stock.

Twist Bioscience Stock Up 6.2 %

Shares of NASDAQ TWST traded up $2.30 during midday trading on Tuesday, hitting $39.41. 1,392,358 shares of the stock traded hands, compared to its average volume of 912,029. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The business has a 50 day moving average price of $47.23 and a two-hundred day moving average price of $45.57. The company has a market cap of $2.35 billion, a PE ratio of -11.67 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience's quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.75) EPS. On average, equities analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.